Abstract
RTS, S/AS01 vaccine has recently been recommended by the WHO for large-scale uses in malaria-endemic areas, which is a milestone in the history of the fight against parasitic infections. Nevertheless, RTS, S/AS01 vaccine is not perfect. Hereby, the shortages of RTS, S/AS01 malaria vaccine were discussed, and the potential challenges during the research and development of next-generation malaria vaccines were analyzed.